tetano
Editor, Senior Moderator
Semin Arthritis Rheum
. 2020 Jun 30;50(5):1150-1157.
doi: 10.1016/j.semarthrit.2020.06.012. Online ahead of print.
COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients
Giuseppe A Ramirez[SUP] 1 [/SUP], Maria Gerosa[SUP] 2 [/SUP], Lorenzo Beretta[SUP] 3 [/SUP], Chiara Bellocchi[SUP] 4 [/SUP], Lorenza M Argolini[SUP] 2 [/SUP], Luca Moroni[SUP] 5 [/SUP], Emanuel Della Torre[SUP] 5 [/SUP], Carolina Artusi[SUP] 2 [/SUP], Selene Nicolosi[SUP] 3 [/SUP], Roberto Caporali[SUP] 2 [/SUP], Enrica P Bozzolo[SUP] 6 [/SUP], Lorenzo Dagna[SUP] 5 [/SUP], SMILE, Milan Lupus Consortium
Affiliations
Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic disease characterised by autoimmunity and increased susceptibility to infections. COVID-19 is a systemic viral disease currently spreading as a pandemic. Little is known about the impact of COVID-19 in patients with SLE.
Objective: to acquire information on the impact of COVID-19 in SLE.
Methods: A 26-item anonymous questionnaire investigating demographics, SLE clinical features, COVID-19 diagnoses and changes in treatments and daily habits was administered to patients with SLE from three referral centres through www.surveymonkey.com over 10 days. Data from the survey were compared to those from published estimates about the general population.
Results: Four-hundred-seventeen patients responded to the survey. More than 60% of subjects complained of symptoms that are also associated to COVID-19. Fourteen COVID-19 diagnoses (five confirmed by polymerase chain reaction) were reported, in contrast to a 0.73% prevalence of confirmed cases in Lombardy. One hospitalisation was reported. Fever, anosmia, dry cough, a self-reported history of neuropsychiatric SLE and a recent contact with confirmed COVID-19 cases were more strongly associated with COVID-19, as were symptoms and lower compliance to behavioural preventive measures in patients' contacts. No protective effect was seen in subjects on hydroxychloroquine.
Conclusion: COVID-19 morbidity might only moderately be increased in most patients with SLE, although limited information can be inferred on more severe cases. Hydroxychloroquine apparently seems not to confer protection to infection per se, although other beneficial roles cannot be excluded. Containment policies and behavioural preventive measures could have a major role in limiting the impact of COVID-19 in patients with SLE.
Keywords: COVID-19; Coronavirus; Epidemiology; Hydroxychloroquine; Systemic lupus erythematosus; Web.
. 2020 Jun 30;50(5):1150-1157.
doi: 10.1016/j.semarthrit.2020.06.012. Online ahead of print.
COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients
Giuseppe A Ramirez[SUP] 1 [/SUP], Maria Gerosa[SUP] 2 [/SUP], Lorenzo Beretta[SUP] 3 [/SUP], Chiara Bellocchi[SUP] 4 [/SUP], Lorenza M Argolini[SUP] 2 [/SUP], Luca Moroni[SUP] 5 [/SUP], Emanuel Della Torre[SUP] 5 [/SUP], Carolina Artusi[SUP] 2 [/SUP], Selene Nicolosi[SUP] 3 [/SUP], Roberto Caporali[SUP] 2 [/SUP], Enrica P Bozzolo[SUP] 6 [/SUP], Lorenzo Dagna[SUP] 5 [/SUP], SMILE, Milan Lupus Consortium
Affiliations
- PMID: 32927376
- DOI: 10.1016/j.semarthrit.2020.06.012
Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic disease characterised by autoimmunity and increased susceptibility to infections. COVID-19 is a systemic viral disease currently spreading as a pandemic. Little is known about the impact of COVID-19 in patients with SLE.
Objective: to acquire information on the impact of COVID-19 in SLE.
Methods: A 26-item anonymous questionnaire investigating demographics, SLE clinical features, COVID-19 diagnoses and changes in treatments and daily habits was administered to patients with SLE from three referral centres through www.surveymonkey.com over 10 days. Data from the survey were compared to those from published estimates about the general population.
Results: Four-hundred-seventeen patients responded to the survey. More than 60% of subjects complained of symptoms that are also associated to COVID-19. Fourteen COVID-19 diagnoses (five confirmed by polymerase chain reaction) were reported, in contrast to a 0.73% prevalence of confirmed cases in Lombardy. One hospitalisation was reported. Fever, anosmia, dry cough, a self-reported history of neuropsychiatric SLE and a recent contact with confirmed COVID-19 cases were more strongly associated with COVID-19, as were symptoms and lower compliance to behavioural preventive measures in patients' contacts. No protective effect was seen in subjects on hydroxychloroquine.
Conclusion: COVID-19 morbidity might only moderately be increased in most patients with SLE, although limited information can be inferred on more severe cases. Hydroxychloroquine apparently seems not to confer protection to infection per se, although other beneficial roles cannot be excluded. Containment policies and behavioural preventive measures could have a major role in limiting the impact of COVID-19 in patients with SLE.
Keywords: COVID-19; Coronavirus; Epidemiology; Hydroxychloroquine; Systemic lupus erythematosus; Web.